Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Video

Updated: May 22, 2026

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases

Published on: May 17, 2019

Multi-modal AI for comprehensive breast cancer prognostication.

Jan Witowski¹, Ken G Zeng¹, Joseph Cappadona¹

¹Ataraxis AI, New York, NY, USA.

Nature Communications

|May 20, 2026

Related Concept Videos

Cancer Survival Analysis

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Distillation enables scalable high-fidelity virtual screening across ultra-large chemical libraries.

bioRxiv : the preprint server for biology·2026

Same author

Refining Stratification in Premenopausal Node-Positive HR<sup>+</sup>/HER2<sup>-</sup> Breast Cancer With a Novel AI-Based Test.

Clinical breast cancer·2026

Same author

Lymphovascular Invasion in SOUND-Eligible Breast Cancer: Implications for Occult Axillary Nodal Metastasis.

Annals of surgical oncology·2026

Same author

Longitudinal multiomics profiling of extracorporeal cross-circulation with pig liver xenografts in human decedents.

Nature medicine·2026

Same author

Vision-language models for human motion understanding: Lessons from stroke rehabilitation.

PLOS digital health·2026

Same author

Primary intraosseous anastomosing hemangioma of the sacrum: illustrative case.

Journal of neurosurgery. Case lessons·2026

Summary

An AI test integrating digital pathology and clinical data improves breast cancer risk prediction. This artificial intelligence approach offers more precise prognostication than standard methods, aiding clinical decisions.

Area of Science:

Oncology
Digital Pathology
Artificial Intelligence

Background:

Breast cancer treatment selection relies on risk assessment using molecular subtypes and clinicopathological data.
Current risk assessment methods lack the precision for optimal clinical decision-making.

Purpose of the Study:

To develop and evaluate an AI test that integrates digital pathology with clinical data for improved breast cancer risk stratification.
To compare the AI test's prognostic performance against the standard-of-care 21-gene assay.

Main Methods:

Utilized data from 8161 breast cancer patients.
Developed an AI test combining digital pathology images and clinical information.
Evaluated the AI test's ability to predict disease-free interval and compared its discrimination to the 21-gene assay.

Related Experiment Videos

Last Updated: May 22, 2026

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases

Published on: May 17, 2019

Main Results:

The AI test demonstrated robust prediction of disease-free interval (C-index: 0.71).
The AI test showed numerically higher discrimination (C-index: 0.67) compared to the 21-gene assay (C-index: 0.61).
The AI test performed well across molecular subtypes, including triple-negative breast cancer (C-index: 0.71).

Conclusions:

AI-based digital pathology tests offer a promising tool for enhanced risk stratification in breast cancer.
The AI test has potential implications for improving clinical decision-making across all major breast cancer subtypes.
The AI test provides robust prognostic performance, particularly in subtypes lacking current guideline-recommended assays.